We are live on ! Find out more
RNAC icon

Cartesian Therapeutics
RNAC

16 hedge funds and large institutions have $105M invested in Cartesian Therapeutics in 2016 Q2 according to their latest regulatory filings, with 16 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
16
Holders Change
+16
Holders Change %
–
% of All Funds
0.43%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
16
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PVMCV
Polaris Venture Management Co V
Massachusetts
+$26.9M
2
O
OrbiMed
New York
+$25.8M
3
PA
Perceptive Advisors
New York
+$6.3M
4
JP Morgan Chase
JP Morgan Chase
New York
+$4.22M
5
UBS Group
UBS Group
Switzerland
+$4.15M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
PVMCV
1
Polaris Venture Management Co V
Massachusetts
$26.9M +$26.9M +64,138 New
O
2
OrbiMed
New York
$25.8M +$25.8M +61,427 New
FV2GP
3
Flagship Ventures 2007 General Partner
Massachusetts
$23.1M +$23.1M +55,062 New
PA
4
Perceptive Advisors
New York
$6.3M +$6.3M +15,000 New
JP Morgan Chase
5
JP Morgan Chase
New York
$4.21M +$4.22M +10,043 New
UBS Group
6
UBS Group
Switzerland
$4.15M +$4.15M +9,891 New
Fidelity Investments
7
Fidelity Investments
Massachusetts
$4M +$4M +9,523 New
BBA
8
Baker Bros. Advisors
New York
$2.5M +$2.51M +5,965 New
Alyeska Investment Group
9
Alyeska Investment Group
Illinois
$2.45M +$2.45M +5,833 New
Vanguard Group
10
Vanguard Group
Pennsylvania
$1.68M +$1.68M +4,000 New
WA
11
Wasatch Advisors
Utah
$1.06M +$1.06M +2,535 New
SSA
12
Schonfeld Strategic Advisors
New York
$656K +$656K +1,562 New
Marshall Wace
13
Marshall Wace
United Kingdom
$506K +$507K +1,207 New
Millennium Management
14
Millennium Management
New York
$358K +$358K +852 New
MIM
15
Monashee Investment Management
Massachusetts
$350K – – –
Goldman Sachs
16
Goldman Sachs
New York
$350K +$350K +833 New
LCM
17
Laurion Capital Management
New York
$350K +$350K +833 New

RNAC Hedge Fund Activity: Q2 2016 in Review

16 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q2 2016, worth a combined $105M.

Buyers outnumbered sellers: 16 funds opened new RNAC positions and 0 closed out — a net gain of 16 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Polaris Venture Management Co V, opening a new position worth an estimated $26.9M.

  • 16 institutional investors held Cartesian Therapeutics (RNAC) as of Q2 2016, up from 0 in Q1 2016.
  • Funds reported $105M of Cartesian Therapeutics stock for Q2 2016.
  • 16 funds opened new Cartesian Therapeutics positions in Q2 2016 and 0 closed out, a net change of +16 holders.
  • The largest Cartesian Therapeutics buyer in Q2 2016 was Polaris Venture Management Co V, an estimated $26.9M added.

Based on aggregated 13F filings for Q2 2016.